The epidemiology of amyotrophic lateral sclerosis (ALS/MND) in people aged 80 or over

Age and Ageing

Volumn 33, Issue 2, 2004, Pages 131-134

  Forbes, Raeburn B ^a   Colville, Shuna ^b   Swingler, Robert J ^b  

^a ROYAL VICTORIA HOSPITAL   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

ALS MND; Amyotrophic lateral sclerosis; Elderly; Epidemiology; Motor neurone disease; Survival

Indexed keywords

RILUZOLE;

AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BULBAR PARALYSIS; CLINICAL FEATURE; CONTROLLED STUDY; ELDERLY CARE; FEMALE; HUMAN; INCIDENCE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MASS SCREENING; NEUROLOGIC EXAMINATION; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANK SUM TEST; REGISTER; SEX DIFFERENCE; STANDARDIZATION; SURVIVAL; UNITED KINGDOM;

AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; PROSPECTIVE STUDIES; SCOTLAND; SURVIVAL ANALYSIS;

EID: 1542329664     PISSN: 00020729     EISSN: None     Source Type: Journal    
DOI: 10.1093/ageing/afh013     Document Type: Article

References (24)

1. Piemonte and Valle d'Aosta Register for Amyotrophic Lateral Sclerosis (PARALS). Incidence of ALS in Italy: evidence for a uniform frequency in Western countries. Neurology 2001; 56: 239-44.
2. Hodkinson H. More favourable prognosis of motor neurone disease in old age. Age Ageing 1972; 1: 182-4.
3. Anonymous. The Scottish Motor Neurone Disease Register: a prospective study of adult onset motor neurone disease in Scotland. Methodology, demography and clinical features of incident cases in 1989. J Neurol Neurosurg Psychiatry 1992; 55: 536-41.
4. Brooks BR. El Escorial World Federation of Neurology criteria for the diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neurone Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research Group on Neuromuscular Diseases and the El Escorial 'Clinical limits of amyotrophic lateral sclerosis' workshop contributors. J Neurol Sci 1994; 124 (Suppl): 96-107.
5. Hook EB, Regal RR. The value of capture recapture methods even for apparent exhaustive surveys. Am J Epidemiol 1992; 135: 1060-5.
6. The General Register Office for Scotland. Mid-1994 Population Estimates. Edinburgh: The General Register Office for Scotland, 1994.
7. Lillienfeld D, Stolley P. Foundations of Epidemiology. 3rd ed. New York: Oxford University Press, 1994.
8. Gardner M, Altman D. Statistics with Confidence. 1st ed. London: BMJ, 1989.
9. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman OM. Clinical features of amyotrophic lateral sclerosis according to the El Escorial and Airlie House diagnostic criteria: a population-based study. Arch Neurol 2000; 57: 1171-6.
10. Chancellor A, Fraser H, Swingler R, Holloway S, Warlow C. Clinical heterogeneity of familial motor neurone disease: report of 11 pedigrees from a population based study in Scotland. The Scottish Motor Neurone Disease Research Group. J Neurol Sci 1994; 124 (Suppl): 75-6.
11. Traynor BJ, Codd MB, Corr B, Forde C, Frost E, Hardiman O. Amyotrophic lateral sclerosis mimic syndromes: a population-based study. Arch Neurol 2000; 57: 109-13.
12. Visser J, Berg-Vos Rvd, Franssen H et al. Mimic syndromes in sporadic cases of progressive spinal muscular atrophy. Neurology 2002; 58: 1593-6.
13. Eisen A, Schulzer M, MacNeil M, Pant B, Mak E. Duration of amyotrophic lateral sclerosis is age dependent. Muscle Nerve 1993; 16: 27-32.
14. Norris F, Shepherd R, Denys E et al. Onset, natural history and outcome in idiopathic adult motor neurone disease. J Neurol Sci 1993; 118: 48-55.
15. Gubbay SS, Kahana E, Zilber N, Cooper G, Pintov S, Leibowitz Y. Amyotrophic lateral sclerosis. A study of its presentation and prognosis. J Neurol 1985; 232: 295-300.
16. Mackay R. Course and prognosis in amyotrophic lateral sclerosis. Arch Neurol 1963; 8: 17-27.
17. Tysnes OB, Vollset SE, Larsen JP, Aarli JA. Prognostic factors and survival in amyotrophic lateral sclerosis. Neuroepidemiology 1994; 13: 226-35.
18. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996; 347: 1425-31.
19. Bensimon G, Lacomblez L, Meininger V. A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group. N Engl J Med 1994; 330: 585-91.
20. Bensimon G, Lacomblez L, Delumeau J et al. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol 2002; 249: 609-15.
21. Miller R. Practice parameter: the care of the patient with amyotrophic lateral sclerosis: report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology 1999; 52: 1311-23.
22. Mazzini L, Corra T, Zaccala M, Mora G, Del Piano M, Galante M. Percutaneous endoscopic gastrostomy and enteral nutrition in amyotrophic lateral sclerosis. J Neurol 1995; 242: 695-8.
23. Mathus-Vliegen LM, Louwerse LS, Merkus MP, Tytgat GN, Vianney de Jong JM. Percutaneous endoscopic gastrostomy in patients with amyotrophic lateral sclerosis and impaired pulmonary function. Gastrointest Endosc 1994; 40: 463-9.
24. Kasarskis EJ, Scarlata D, Hill R, Fuller C, Stambler N, Cedarbaum JM. A retrospective study of percutaneous endoscopic gastrostomy in ALS patients during the BDNF and CNTF trials. J Neurol Sci 1999; 169: 118-25.